Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, EpiSciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

[Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].

Abstract : Hypereosinophilic syndromes (HES) are a heterogeneous group of disorders characterized by marked peripheral blood and tissue eosinophilia resulting in organ damage. Recent advances in molecular biology have led to the identification of a FIP1L1-PDGFRA fusion gene as a recurrent abnormality in some patients with HES. This fusion gene results from a cryptic 4q12 interstitial deletion involving an 800 kb region. Recent reports indicate that this subtype of HES is imatinib responsive with rapid and complete haematological remissions. Here we report two patients successfully treated with imatinib.
Document type :
Journal articles
Complete list of metadata
Contributor : Institut Pasteur Tunis Connect in order to contact the contributor
Submitted on : Wednesday, October 9, 2013 - 4:29:57 PM
Last modification on : Monday, January 4, 2021 - 3:58:10 PM

Links full text




S. Menif, N. Ben Romdhane, R. Hafsia. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].. La Revue De Médecine Interne, Elsevier, 2008, 29 (1), pp.65-7. ⟨10.1016/j.revmed.2007.09.036⟩. ⟨pasteur-00871496⟩



Record views